Grolatine

**Grolatine** is an unapproved, orally administered full-spectrum phytocannabinoid extract developed by GrowLab Pharmaceuticals. The product is described by its developer as a proprietary cannabis-derived nanoemulsion containing cannabidiol, tetrahydrocannabinol, terpenes, and other cannabis-plant constituents. GrowLab has presented Grolatine as an investigational therapy for chronic pain and sickle cell disease-associated pain crises; however, publicly accessible evidence located for the exact product consists principally of company materials and company-distributed press releases rather than a registered interventional trial record or peer-reviewed clinical publication. The company has claimed that low-dose administration promotes smooth-muscle relaxation and generalized vasodilation, potentially reducing vaso-occlusive processes in sickle cell disease, but this proposed mechanism has not been independently established for Grolatine. ([growlabplc.com](https://growlabplc.com/grolatine/))

Brand names

Grolatine